cas 2228029-82-9|| where to buy 2-(2,6-dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline-1,3-dione;hydrochloride

Produktname:2-(2,6-dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline-1,3-dione;hydrochloride

IUPAC Name:2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione hydrochloride

: CAS：2228029-82-9; Molekulare Formel：C17H19ClN4O4; Reinheit：97%

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM1076761-100mg	in stock	ȋǠǆ
CM1076761-250mg	in stock	şȋŸ
CM1076761-500mg	in stock	şƚǆ
CM1076761-1g	in stock	œǠȤ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2228029-82-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2228029-82-9; Molekulare Formel:C17H19ClN4O4; Schmelzpunkt:-; SMILES-Code:Cl.O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC(=CC=C12)N1CCNCC1; Dichte:

: Katalognummer:CM1076761; Molekulargewicht:378.81; Siedepunkt:; Mdl-Nr.:; Lagerung:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.